ANGLE review points to liquid biopsy's potential to guide head and neck cancer treatment

The assessment was carried out by the University of Birmingham

The Parsortix system detects the tell-tale signs of cancer

ANGLE PLC (LON:AGL,OTCQX:ANPCY) said a review of its ground-breaking liquid biopsy has identified “advantages” to using the technology when treating head and neck cancer patients.

The Parsortix system detects the tell-tell signs of cancer in the form of circulating tumour cells found in the blood.

In the assessment carried out by the University of Birmingham, the device was shown to help accurately assess and grade risk and was also able to help doctors decide treatment options.

Specifically, physicians were able to predict responses to certain medications and spot the failures early so a shift could be made to a more appropriate drug likely to give a better response.

The researcher said the device may even be able to guide doctors as to which of their cancer patients might be candidates for the new immunotherapies coming through.

Being a liquid biopsy, repeat samples were able to be taken. Traditional biopsies take tissue, which can often be a painful process, so the option to make multiple follow-ups is limited.

Finally, the Birmingham team found Parsortix overcame some of the limitations encountered by rival antibody-based liquid systems.

"This review of current research clearly identifies the potential for using CTC liquid biopsies to improve treatment of head and neck cancer,” said Andrew Newland, ANGLE’s chief executive.

“We are pleased that key advantages of ANGLE's Parsortix system have been recognised and believe that head and neck cancer is another opportunity for ANGLE, once we have our own clinical laboratory established."

Quick facts: ANGLE PLC

Price: 54.3 GBX

Market: AIM
Market Cap: £93.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read